
Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.
The American Journal of Managed Care
over 27 years ago
The State of Behavioral Health in Managed Careover 27 years ago
Managed Public Mental Healthcare: Issues, Trends, and Prospects





